Psyence Group’s Associate Advances Psilocybin Trial
Company Announcements

Psyence Group’s Associate Advances Psilocybin Trial

Psyence Group Inc. (TSE:PSYG) has released an update.

Psyence Group Inc. is advancing in the mental health sector by having its associate, Psyence Biomed, partner with Fluence and iNGENū CRO to facilitate training for a Phase IIb clinical trial involving psilocybin, a natural psychedelic compound. The collaboration aims to integrate psychedelic-assisted therapy for palliative medicine, with a trial set to begin in the second quarter of 2024, testing psilocybin in conjunction with psychotherapy on 84 patients. Psyence Group, known for its federally licensed commercial psilocybin production facility, holds a significant minority interest in Psyence Biomed.

For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Sells Stake to Psyence Biomedical
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Expands Psilocybin Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Enhances Liquidity with Equity Swap
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App